Publications
-
-
-
-
-
-
-
-
-
-
Tajik, Athar Ali; Dobre, Daniela; Aguilar, David; Kjekshus, John; Zannad, Faiez & Dickstein, Kenneth
(2017).
A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the High-Risk MI Database.
European Journal of Heart Failure.
ISSN 1388-9842.
19(5),
p. 635–642.
doi:
10.1002/ejhf.797.
-
-
Arain, Fizza Kanwal; Gullestad, Lars; Nymo, Ståle Haugset; Kjekshus, John; Cleland, JG & Michelsen, Annika
[Show all 10 contributors for this article]
(2016).
Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA.
Biomarkers.
ISSN 1354-750X.
22(3-4),
p. 261–267.
doi:
10.1080/1354750X.2016.1204003.
-
-
-
-
-
Abdul-Rahim, Azmil H.; Perez, Ana-Cristina; Fulton, Rachael L.; Jhund, Pardeep S.; Latini, Roberto & Tognoni, Gianni
[Show all 13 contributors for this article]
(2015).
Risk of stroke in chronic heart failure patients without atrial fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza cardiaca-Heart Failure (GISSI-HF) trials.
Circulation.
ISSN 0009-7322.
131(17),
p. 1486–1494.
doi:
10.1161/CIRCULATIONAHA.114.013760.
-
-
-
-
-
Wethal, Torgeir; Røysland, Ragnhild; Omland, Torbjørn & Kjekshus, John
(2015).
Exercise-induced vasodilation in healthy males: A marker of reduced endothelial function.
Scandinavian Cardiovascular Journal.
ISSN 1401-7431.
49(3),
p. 123–129.
doi:
10.3109/14017431.2015.1021708.
-
Ueland, Thor; Aukrust, Pål; Nymo, Ståle Haugset; Kjekshus, John; McMurray, John J.V. & Wikstrand, John
[Show all 10 contributors for this article]
(2015).
Predictive Value of Endostatin in
Chronic Heart Failure Patients with
Poor Kidney Function.
Cardiology.
ISSN 0008-6312.
130(1),
p. 17–22.
doi:
10.1159/000368220.
Show summary
OBJECTIVES:
Increased circulating endostatin levels have been demonstrated in progressive cardiovascular (CV) and renal disorders. We investigated the predictive value of endostatin in patients with chronic heart failure (HF) and the association between endostatin and renal function.
METHODS:
The interaction between serum endostatin, estimated glomerular filtration rate (eGFR) and predefined endpoints, including the primary endpoint (CV death, nonfatal myocardial infarction, nonfatal stroke; n = 397), all-cause mortality (n = 410), CV death (n = 335) or the coronary endpoint (n = 317), was evaluated in 1,390 patients >60 years of age with ischemic systolic HF in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) population, who were randomly assigned to 10 mg rosuvastatin or placebo.
RESULTS:
In the population as a whole, endostatin added no predictive information after full multivariable adjustment including eGFR and N-terminal pro-brain natriuretic peptide. Serum endostatin was strongly correlated with eGFR (r = 0.59, p < 0.001). After full multivariable adjustment, an association between high serum endostatin and increased risk of all-cause mortality and decreased risk of the primary and coronary endpoints was seen in HF patients with impaired and preserved renal function, respectively.
CONCLUSIONS:
Endostatin added no predictive information regarding the adverse outcome in patients with chronic systolic HF of ischemic etiology. An increased risk of all-cause mortality was seen in patients with decreased renal function.
-
Ueland, Thor; Aukrust, Pål; Nymo, Ståle Haugset; Kjekshus, John; McMurray, JJ & Wikstrand, J
[Show all 9 contributors for this article]
(2015).
Novel Extracellular Matrix Biomarkers as Predictors of Adverse Outcome in Chronic Heart Failure: Association Between Biglycan and Response to Statin Therapy in the CORONA Trial.
Journal of Cardiac Failure.
ISSN 1071-9164.
21(2),
p. 153–159.
doi:
10.1016/j.cardfail.2014.10.016.
Show summary
BACKGROUND:
The extracellular matrix (ECM) plays an important role in left ventricular remodeling and progression of heart failure (HF). Biglycan and mimecan are ECM proteins that are abundantly expressed in cardiac tissue but have not been evaluated as prognostic markers in HF. We investigated their interaction with statin treatment and association with adverse outcome in chronic HF.
METHODS AND RESULTS:
The association between serum levels of biglycan and mimecan and the primary end point (cardiovascular [CV] death, nonfatal myocardial infarction, nonfatal stroke), all-cause mortality, CV death, the composite of all-cause mortality/hospitalization for worsening of HF, and the coronary end point was evaluated in 1,390 patients >60 years of age with ischemic systolic HF in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) population, randomly assigned to 10 mg rosuvastatin or placebo. Serum biglycan and mimecan added no prognostic information beyond conventional risk factors, including N-terminal pro-B-type natriuretic peptide. However, statin treatment improved all outcomes except CV death in patients with low biglycan levels (ie, lower tertile), even after full multivariable adjustment.
CONCLUSIONS:
Although circulating levels of mimecan and biglycan were of limited predictive value in patients with chronic HF, circulating biglycan could be a useful marker for targeting statin therapy in patients with HF.
-
-
Batty, J.A.; Hall, A.S.; White, H.L.; Wikstrand, J.; de Boer, R.A. & van Veldhuisen, D.J.
[Show all 11 contributors for this article]
(2014).
An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure: A MERIT-HF Substudy.
Clinical Pharmacology and Therapeutics.
ISSN 0009-9236.
95(3),
p. 321–330.
doi:
10.1038/clpt.2013.193.
-
-
Badar, Athar A.; Perez-Moreno, Ana Cristina; Jhund, Pardeep S.; Wong, Chih M.; Hawkins, Nathaniel M. & Cleland, John G F
[Show all 14 contributors for this article]
(2014).
Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
European Heart Journal.
ISSN 0195-668X.
35(48),
p. 3426–3433.
doi:
10.1093/eurheartj/ehu342.
-
Kristensen, Søren L.; Køber, Lars; Jhund, Pardeep S; Solomon, Scott D.; Kjekshus, John & McKelvie, Robert S.
[Show all 16 contributors for this article]
(2014).
International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction.
Circulation: Heart Failure.
ISSN 1941-3289.
doi:
10.1161/CIRCULATIONAHA.114.012284.
Show summary
Background—International geographic differences in outcomes may exist for clinical trials of heart failure and reduced ejection fraction (HF-REF), but there are few data for those with preserved ejection fraction (HF-PEF).
Methods and Results—We analyzed outcomes by international geographic region in the Irbesartan in Heart Failure with Preserved systolic function trial (I-Preserve), the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved trial, the CHARM-Alternative and CHARM–Added HF-REF trials, and the Controlled Rosuvastatin Multinational Trial in HF-REF (CORONA). Crude rates of heart failure hospitalization varied by geographic region, and more so for HF-PEF than for HF-REF. Rates in patients with HF-PEF were highest in the United States/Canada (HF hospitalization rate 7.6 per 100 patient-years in I-Preserve; 8.8 in CHARM-Preserved), intermediate in Western Europe (4.8/100 and 4.7/100), and lowest in Eastern Europe/Russia (3.3/100 and 2.8/100). The difference between the United States/Canada versus Eastern Europe/Russia persisted after adjustment for key prognostic variables: adjusted hazard ratios 1.34 (95% confidence interval, 1.01–1.74; P=0.04) in I-Preserve and 1.85 (95% confidence interval, 1.17–2.91; P=0.01) in CHARM-Preserved. In HF-REF, rates of HF hospitalization were slightly lower in Western Europe compared with other regions. For both HF-REF and HF-PEF, there were few regional differences in rates of all-cause or cardiovascular mortality.
Conclusions—The differences in event rates observed suggest there is international geographic variation in 1 or more of the definition and diagnosis of HF-PEF, the risk profile of patients enrolled, and the threshold for hospitalization, which has implications for the conduct of future global trials.
-
-
-
-
-
Gravning, Jørgen A.; Askevold, Erik Tandberg; Nymo, Ståle Haugset; Ueland, Thor; Wikstrand, John & McMurray, John J.V.
[Show all 9 contributors for this article]
(2014).
Prognostic effect of high-sensitive troponin t assessment in elderly patients with chronic heart failure results from the CORONA Trial.
Circulation: Heart Failure.
ISSN 1941-3289.
7(1),
p. 96–103.
doi:
10.1161/CIRCHEARTFAILURE.113.000450.
-
-
Inglis, Sally C.; Bebchuk, Judith; Al-Suhaim, Sultan A.; Case, Jessica; Pfeffer, Marc A. & Solomon, Scott D.
[Show all 14 contributors for this article]
(2013).
Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT.
International Journal of Cardiology.
ISSN 0167-5273.
168(2),
p. 1094–1101.
doi:
10.1016/j.ijcard.2012.11.033.
-
-
-
-
-
-
Kåsin, Jan Ivar; Kjellevand, Tor Ole; Kjekshus, John; Nesheim, Geir B. & Wagstaff, Anthony Sverre
(2012).
CT Examination of the Pericardium and Lungs in Helicopter Pilots Exposed to Vibration and Noise.
Aviation, Space and Environmental Medicine.
ISSN 0095-6562.
83(9),
p. 858–864.
doi:
10.3357/ASEM.3209.2012.
-
Preiss, David; Tikkanen, Matti J.; Welsh, Paul; Ford, Ian; Lovato, Laura C. & Elam, Marshall B.
[Show all 18 contributors for this article]
(2012).
Lipid-modifying therapies and risk of pancreatitis : a meta-analysis.
Journal of the American Medical Association (JAMA).
ISSN 0098-7484.
308(8),
p. 804–811.
doi:
10.1001/jama.2012.8439.
-
-
Nymo, Ståle Haugset; Ueland, Thor; Askevold, Erik Tandberg; Flo, Trude Helen; Kjekshus, John & Hulthe, Johannes
[Show all 12 contributors for this article]
(2012).
The association between neutrophil gelatinase-associated lipocalin and clinical outcome in chronic heart failure: results from CORONA.
Journal of Internal Medicine.
ISSN 0954-6820.
271(5),
p. 436–443.
doi:
10.1111/j.1365-2796.2011.02503.x.
-
-
-
-
-
Wethal, Torgeir; Haugnes, Hege Sagstuen; Kjekshus, John; Småstuen, Milada C; Ueland, Thor & Aukrust, Pål
[Show all 7 contributors for this article]
(2010).
C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors?
International Journal of Cancer.
ISSN 0020-7136.
46,
p. 3425–3433.
doi:
10.1016/j.ejca.2010.08.004.
-
-
-
-
-
-
Kjekshus, John
(2009).
Statins and heart failure.
In Tonkin, AM (Eds.),
Therapeutic Strategies in Lipid Disorders.
Clinical Publishing.
ISSN 9781846920349.
p. 143–154.
-
Ghali, JK; Wikstrand, John; Van Veldhuisen, D J; Fagerberg, Bjørn; Goldstein, Sidney & Hjalmarson, A
[Show all 12 contributors for this article]
(2009).
The Influence of Renal Function on Clinical Outcome and Response to beta-Blockade in Systolic Heart Failure: Insights From Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF).
Journal of Cardiac Failure.
ISSN 1071-9164.
15(4),
p. 310–318.
doi:
10.1016/j.cardfail.2008.11.003.
-
-
Yndestad, A; Landrø, Linn; Ueland, Thor; Dahl, CP; Flo, Trude Helen & Vinge, Leif Erik
[Show all 15 contributors for this article]
(2009).
Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure.
European Heart Journal.
ISSN 0195-668X.
30(10),
p. 1229–1236.
doi:
10.1093/eurheartj/ehp088.
Show summary
Aims: Neutrophil gelatinase-associated lipocalin (NGAL or lipocalin-2) is a glycoprotein with bacteriostatic properties. Growing evidence suggests that NGAL may also be involved in cell survival, inflammation, and matrix degradation. We therefore aimed to investigate the role of NGAL in heart failure (HF).
Methods and results: Our main findings were (i) patients with acute post-myocardial infarction (MI) HF (n = 236) and chronic HF (n = 150) had elevated serum levels of NGAL (determined by enzyme immunoassay), significantly correlated with clinical and neurohormonal deterioration, (ii) in patients with HF following acute MI, elevated NGAL levels of at baseline were associated with adverse outcomes (median of 27 months follow-up), (iii) in a rat model of post-MI HF, NGAL/lipocalin-2 gene expression was increased in the non-ischaemic part of the left ventricle primarily located to cardiomyocytes, (iv) strong NGAL immunostaining was found in cardiomyocytes within the failing myocardium both in experimental and clinical HF, (v) interleukin-1β and agonists for toll-like receptors 2 and 4, representing components of the innate immune system, were potent inducers of NGAL/lipocalin-2 in isolated neonatal cardiomyocytes.
Conclusion: Our demonstration of enhanced systemic and myocardial NGAL expression in clinical and experimental HF further support a role for innate immune responses in the pathogenesis of HF.
-
-
-
McMurray, John J.V.; Kjekshus, John; Gullestad, Lars; Dunselman, Peter; Hjalmarson, Åke & Wedel, Hans
[Show all 16 contributors for this article]
(2009).
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA). A retrospective analysis.
Circulation.
ISSN 0009-7322.
120(22),
p. 2188–U51.
doi:
10.1161/CIRCULATIONAHA.109.849117.
-
Kasin, JI; Kjekshus, John; Aukrust, Pål; Mollnes, Tom Eirik & Wagstaff, A. S.
(2009).
A helicopter flight does not induce significant changes in systemic biomarker profiles.
Scandinavian Journal of Clinical and Laboratory Investigation.
ISSN 0036-5513.
69(4),
p. 462–474.
doi:
10.1080/00365510902745360.
-
-
-
-
Gravning, J; Ueland, T; Mørkrid, Lars; Endresen, Knut; Aaberge, Lars & Kjekshus, John
(2008).
Different prognostic importance of elevated troponin I after percutaneous coronary intervention in acute coronary syndrome and stable angina pectoris.
Scandinavian Cardiovascular Journal.
ISSN 1401-7431.
42,
p. 214–221.
doi:
10.1080/14017430801932824.
-
Gullestad, Lars & Kjekshus, John
(2008).
Hjertemedisinsk forskning - et lotteri?
Dagens medisin.
ISSN 1501-4290.
3.
-
Huskey, J; Lindenfeld, J; Cook, T; Targher, G; Kendrick, J & Kjekshus, John
[Show all 8 contributors for this article]
(2008).
Effect of simvastatin on kidney function loss in patients with coronary heart disease Findings from the Scandinavian Simvastatin Survival Study (4S).
Atherosclerosis.
ISSN 0021-9150.
-
Kjekshus, John; Arnesen, Harald & Gullestad, Lars
(2007).
Klinisk forskning: medikamentell behandling.
In Forfang, Kolbjørn & Rasmussen, Knut (Ed.),
Det norske hjerte. Norsk hjertemedisins historie.
Universitetsforlaget.
ISSN 978-82-15-00891-2.
p. 293–310.
-
Chonchol, M; Cook, T; Kjekshus, John; Pedersen, TR & Lindenfeld, J
(2007).
Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
American Journal of Kidney Diseases.
ISSN 0272-6386.
49,
p. 373–382.
doi:
10.1053/j.ajkd.2006.11.043.
-
-
-
Damås, Jan Kristian; Smith, Camilla; Øie, Erik; Fevang, Børre; Halvorsen, Bente & Waehre, Torgun
[Show all 19 contributors for this article]
(2007).
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis - Possible pathogenic role in plaque destabilization.
Arteriosclerosis, Thrombosis and Vascular Biology.
ISSN 1079-5642.
27,
p. 614–620.
doi:
10.1161/01.ATV.0000255581.38523.7c.
-
Dickstein, Kenneth; Gleim, Gilbert W.; Snappin, Steven; Snapinn, Steven M.; James, Margaret K. & Kjekshus, John
(2006).
The impact of morbid events on survival following hospitalization for complicated myocardial infarction.
European Journal of Heart Failure.
ISSN 1388-9842.
8(1),
p. 74–80.
doi:
10.1016/j.ejheart.2005.04.010.
-
Waaler, Bjarne; Hisdal, Jonny; Ihlen, Halfdan & Kjekshus, John
(2006).
Mechanisms behind the postprandial increase in cardiac output: a clue obtained from transplanted hearts.
European Journal of Applied Physiology.
ISSN 1439-6319.
97,
p. 516–520.
-
Gravning, Jørgen A.; Vege, Åshild & Kjekshus, John
(2006).
Plutselig uventet dødsfall etter perkutan koronar intervensjon.
Tidsskrift for Den norske legeforening.
ISSN 0029-2001.
24(126),
p. 2111–2113.
-
Holm, Torbjørn; Ueland, Thor; Halvorsen, Bente ; Hognestad, Aina; Holm, A.G. & Wergeland, Ragnhild
[Show all 9 contributors for this article]
(2006).
A protective anti-inflammatory phenotype in high-risk individuals who do not develop coronary artery disease.
JACC.
ISSN 1021-8009.
47(5),
p. 1085–1086.
-
Kennedy, L M; Anker, S D; Kjekshus, John; Cook, TJ & Willenheimer, R
(2006).
Impact of neurohormonal blockade on association between body mass index and mortality.
International Journal of Cardiology.
ISSN 0167-5273.
-
-
Kjekshus, John
(2006).
The effect of heart rate reduction on survival in heart failure.
Medicographia.
ISSN 0243-3397.
28,
p. 238–244.
View all works in Cristin
-
Abdul-Rahim, Azmil H.; Perez, Ana-Cristina; Fulton, Rachael L.; Jhund, Pardeep S.; Latini, Roberto & Tognoni, Gianni
[Show all 13 contributors for this article]
(2015).
Response to Letter Regarding Article, "risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials".
Circulation.
ISSN 0009-7322.
132(22).
doi:
10.1161/CIRCULATIONAHA.115.018395.
-
-
Dobre, D.; Zannad, F.; Kjekshus, John & Dickstein, Kenneth
(2013).
The association between heart rate, pulse pressure and clinical outcomes in 16503 patients with myocardial infarction complicated by signs of heart failure or left ventricular dysfunction.
European Heart Journal.
ISSN 0195-668X.
34,
p. 349–349.
-
-
-
Gravning, Jørgen A.; Askevold, Erik Tandberg; Nymo, Ståle Haugset; Ueland, Thor; Wergeland, Ragnhild & Wikstrand, J
[Show all 9 contributors for this article]
(2012).
Prognostic impact of high-sensitive troponin T assessment in chronic heart failure and interaction with statin therapy. Results from CORONA.
European Heart Journal.
ISSN 0195-668X.
33,
p. 644–645.
-
-
-
Kjekshus, John
(2009).
Is there a heart rate paradox - demystification of the myths?
Journal of Internal Medicine.
ISSN 0954-6820.
266(3),
p. 242–247.
doi:
10.1111/j.1365-2796.2009.02143.x.
-
Inglis, S; McMurray, J; Wedel, H; Dunselman, P; Kjekshus, John & Hjalmarson, A
[Show all 8 contributors for this article]
(2009).
Intermittent claudication as a new predictor of outcome in heart failure: evidence from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
-
-
-
Gravning, Jørgen Amundsen & Kjekshus, John
(2008).
The perfect biomarker in acute coronary syndrome: a challenge for diagnosis, prognosis, and treatment.
European Heart Journal.
ISSN 0195-668X.
29(23),
p. 2827–2828.
doi:
10.1093/eurheartj/ehn489.
-
-
-
Kjekshus, John; Edvardsen, Thor; Gullestad, Lars; Koeber, L; Osnes, Jan-Bjørn & Qvigstad, Erik
[Show all 10 contributors for this article]
(2008).
The effect of Piboserod a 5-HT4-receptor antagonist on left ventricular function in patients with symptomatic heart failure.
-
Wethal, Torgeir; Lund, May Brit; Fosså, Sophie Dorothea; Kjekshus, John; Edvardsen, Thor & Pripp, AH
[Show all 8 contributors for this article]
(2008).
Late onset valvular and myocardial dysfunction in Hodgkin lymphoma survivors.
-
Kjekshus, John
(2007).
Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival.
European Journal of Heart Failure.
ISSN 1388-9842.
9,
p. 962–963.
-
View all works in Cristin
Published
Dec. 17, 2013 10:31 AM
- Last modified
Dec. 17, 2013 10:31 AM